Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | KDM2B | Q8NHM5 | 9/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24110522 | 0.96 | HTR2C (0.43) | HTR2CKDM2BHRH3POLBHTR6 | |
| SCHEMBL24110507 | 0.88 | KDM4E (0.41) | HTR2CKDM2BHRH3POLBHTR6 | |
| SCHEMBL24110142 | 0.84 | HTR2C (0.41) | HTR2CKDM2BPOLBHTR6L3MBTL1 | |
| SCHEMBL25817962 | 0.83 | HTR2C (0.39) | HTR2CKDM2BPOLBHTR6L3MBTL1 | |
| SCHEMBL24110524 | 0.82 | HTR2C (0.39) | HTR2CKDM2BHRH3POLBHTR6 | |
| SCHEMBL17602083 | 0.81 | KDM4C (0.47) | HTR2CKDM2BPOLBHTR6L3MBTL1 | |
| SCHEMBL24109934 | 0.81 | HTR2C (0.41) | HTR2CKDM2BPOLBHTR6L3MBTL1 | |
| SCHEMBL24109763 | 0.80 | HTR2C (0.40) | HTR2CKDM2BPOLBHTR6L3MBTL1 | |
| SCHEMBL24109843 | 0.80 | HTR2C (0.42) | HTR2CPOLBHTR6L3MBTL1TFPI2 | |
| SCHEMBL24110627 | 0.80 | HTR2C (0.42) | HTR2CPOLBHTR6L3MBTL1TFPI2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| WO-2021252692-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | GAP43, SLC18A2, PNMT | HTR2C 35/4885KDM2B 2802/4885HRH3 845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.